@arob1000

New data from our prostate cancer T-Cell Engager was just released and it is significantly helped 82% of patients with aggressive metastatic prostate cancer who were out of options with some patients showing lasting tumor regression with few mild side effects. It’s days like this that keep be engaged in my work…I was involved with the development of this drug since it was just an idea 💡, it’s great to see it transforming patients lives and very exciting to have such positive clinical trial results. 🧬 🧪 More info here if anyone is interested. https://investors.vir.bio/news/news-details/2026/Vir-Biotechnology-Reports-Positive-Updated-Phase-1-Results-for-PSMA-targeting-PRO-XTEN-Dual-masked-T-Cell-Engager-VIR-5500-in-Patients-with-Metastatic-Prostate-Cancer/default.aspx

3 replies

6 recasts

31 reactions